Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
|ClinicalTrials.gov Identifier: NCT00728598|
Recruitment Status : Completed
First Posted : August 6, 2008
Last Update Posted : August 6, 2008
|Condition or disease|
|Proliferative Diabetic Retinopathy Angiogenesis|
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||Vitreous Levels of Patients With Proliferative Diabetic Retinopathy.|
|Study Start Date :||January 1998|
|Actual Primary Completion Date :||December 1998|
|Actual Study Completion Date :||December 1998|
Proliferative diabetic retinopathy, active.
Proliferative diabetic retinopathy, quiescent.
Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
- Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor. [ Time Frame: vitreous sample collected on vitrectomy ]
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00728598
|The department of ophthalmology, National Taiwan University Hospital|
|Principal Investigator:||Chang-Hao Yang, MD, PhD||Ophthalmology, National Taiwan University Hospital|